Avalo Cash Flow To Debt Ratio from 2010 to 2024

AVTX Stock  USD 10.13  0.48  4.97%   
Avalo Therapeutics Cash Flow To Debt Ratio yearly trend continues to be fairly stable with very little volatility. Cash Flow To Debt Ratio will likely drop to -1.3 in 2024. During the period from 2010 to 2024, Avalo Therapeutics Cash Flow To Debt Ratio regression line of annual values had significance of  0.35 and arithmetic mean of (2.23). View All Fundamentals
 
Cash Flow To Debt Ratio  
First Reported
2010-12-31
Previous Quarter
(1.24)
Current Value
(1.30)
Quarterly Volatility
1.14904601
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 150.1 K, Interest Expense of 5.6 M or Selling General Administrative of 11.9 M, as well as many indicators such as Price To Sales Ratio of 1.25, Dividend Yield of 0.0 or PTB Ratio of 0.33. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Avalo Therapeutics Correlation against competitors.
For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Latest Avalo Therapeutics' Cash Flow To Debt Ratio Growth Pattern

Below is the plot of the Cash Flow To Debt Ratio of Avalo Therapeutics over the last few years. It is Avalo Therapeutics' Cash Flow To Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flow To Debt Ratio10 Years Trend
Pretty Stable
   Cash Flow To Debt Ratio   
       Timeline  

Avalo Cash Flow To Debt Ratio Regression Statistics

Arithmetic Mean(2.23)
Coefficient Of Variation(51.47)
Mean Deviation0.53
Median(2.15)
Standard Deviation1.15
Sample Variance1.32
Range4.9517
R-Value0.26
Mean Square Error1.33
R-Squared0.07
Significance0.35
Slope0.07
Total Sum of Squares18.48

Avalo Cash Flow To Debt Ratio History

2024 -1.3
2023 -1.24
2022 -1.38
2017 -2.16
2016 -6.19
2015 -1.83

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' Cash Flow To Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flow To Debt Ratio(1.24)(1.30)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.